PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-245.34%
Negative EBIT growth while AGEN is at 18.38%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-249.64%
Negative operating income growth while AGEN is at 18.38%. Joel Greenblatt would press for urgent turnaround measures.
-146.74%
Negative net income growth while AGEN stands at 117.52%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-145.19%
Negative EPS growth while AGEN is at 116.22%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-145.19%
Negative diluted EPS growth while AGEN is at 116.22%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
39.81%
OCF growth 1.25-1.5x AGEN's 33.58%. Bruce Berkowitz would see if superior pricing or efficient operations explain the gap.
39.81%
FCF growth 1.25-1.5x AGEN's 32.35%. Bruce Berkowitz would see if capex decisions or cost controls create a cash flow advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
21.38%
10Y OCF/share CAGR under 50% of AGEN's 83.32%. Michael Burry would worry about a persistent underperformance in cash creation.
21.38%
Below 50% of AGEN's 88.41%. Michael Burry would be alarmed about sustained underperformance in generating free operational cash.
21.38%
3Y OCF/share CAGR under 50% of AGEN's 79.45%. Michael Burry would worry about a significant short-term disadvantage in generating operational cash.
-13.41%
Negative 10Y net income/share CAGR while AGEN is at 101.64%. Joel Greenblatt sees a major red flag in long-term profit erosion.
-13.41%
Negative 5Y net income/share CAGR while AGEN is 105.39%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
-13.41%
Negative 3Y CAGR while AGEN is 108.21%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.
-423.21%
Both are negative. Martin Whitman suspects the segment is in decline or saddled with persistent unprofitability or write-downs.
-423.21%
Both show negative equity/share growth mid-term. Martin Whitman suspects cyclical or structural challenges for each company.
-423.21%
Negative 3Y equity/share growth while AGEN is at 50.30%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.12%
Both reduce assets yoy. Martin Whitman suspects a broader sector retraction or post-boom asset trimming cycle.
-10.94%
We have a declining book value while AGEN shows 14.48%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.
4.78%
Debt growth far above AGEN's 3.18%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
No Data
No Data available this quarter, please select a different quarter.
231.81%
We expand SG&A while AGEN cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.